Human monoclonal antibody–based quantification of group 2 grass pollen allergens - 24/08/11
Abstract |
Background |
Grasses belong to the most potent allergen sources worldwide. Group 2 grass pollen allergens are recognized by more than 100 million allergic patients.
Objective |
The aim was to develop an assay for the specific detection and quantification of group 2 grass pollen allergens.
Methods |
We have isolated a monoclonal human IgE Fab specific for group 2 grass pollen allergens by combinatorial cloning from lymphocytes of a grass pollen–allergic patient. This Fab was converted into a complete human IgG1 antibody and used together with rPhl p 2 to develop a competitive ELISA for the specific measurement of group 2 allergens. ELISA plate-bound purified recombinant human Phl p 2–specific IgG1 is incubated with a constant amount of biotinylated rPhl p 2 competing with increasing concentrations of group 2 allergens to be determined. Defined concentrations of purified rPhl p 2 are used to establish a standard curve. The concentration of unlabeled group 2 allergens can thus be deduced from the displacement of biotinylated rPhl p 2, which can be detected with peroxidase-labeled streptavidin.
Results |
The competition-ELISA measured rPhl p 2 concentrations ranging from 10 ng/mL to 500 ng/mL and allowed to quantify group 2 allergens from 9 different grass families. The results were in good agreement with immunoblot data.
Conclusions |
The described assay can be used for standardization of diagnostic and therapeutic vaccines as well as for the quantification of group 2 allergens in environmental samples.
Le texte complet de cet article est disponible en PDF.Keywords : Grass pollen allergy, group 2 allergens, competitive ELISA, allergen measurement, recombinant human antibody, recombinant allergen
Abbreviations : r
Plan
| Supported by grants Y078GEN, F01801, T163, and T165-B09 of the Austrian Science Fund and by the CeMM project of the Austrian Academy of Sciences. |
Vol 113 - N° 3
P. 470-474 - mars 2004 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
